Literature DB >> 25604687

Microarray analysis of gene expression in fibrovascular membranes excised from patients with proliferative diabetic retinopathy.

Keijiro Ishikawa1, Shigeo Yoshida1, Yoshiyuki Kobayashi1, Yedi Zhou1, Takahito Nakama1, Shintaro Nakao1, Yukio Sassa2, Yuji Oshima1, Hiroaki Niiro3, Koichi Akashi3, Toshihiro Kono4, Tatsuro Ishibashi1.   

Abstract

PURPOSE: We determined the profile of genes expressed in fibrovascular membranes (FVMs).
METHODS: Six FVMs were surgically removed from patients with proliferative diabetic retinopathy (PDR) during pars plana vitrectomy with membrane peeling. The FVMs were classified into three active FVMs or three inactive FVMs according to the presence or absence of neovascularization (NV) in the membranes. Total RNA was isolated from the six FVMs and also from three normal human retinas. The DNA microarray analysis was performed to compare the genes expressed in the FVMs to those in normal human retinas, and also between active and inactive FVMs. Ingenuity pathway analysis (IPA) was used to determine the key biological networks related to the genes that were significantly altered. Quantitative RT-PCR and immunohistochemistry were performed to validate the microarray analyses.
RESULTS: There were 87 genes expressed at significantly higher levels in FVMs than in normal human retinas. Functional classification of these genes showed that the most clustered genes were those related to extracellular matrix formation. The top biological network generated by the IPA was cellular assembly and organization involving nodes of genes related to extracellular matrix formation. These networks included the collagen family and matricellular proteins, THBS2, POSTN, and TNC. There were 91 genes significantly upregulated in active FVMs, and the most clustered functional category was angiogenesis. In contrast, 89 genes were significantly upregulated in inactive FVMs, and the most clustered functional category was metabolism. The IPA revealed that the top biological network related to the genes that were significantly altered in this comparison was cell-to-cell signaling, and interactions involving the PDGF and TGFβ families. The results of quantitative RT-PCR analyses and immunohistochemistry for several selected molecules were in good agreement with the microarray data.
CONCLUSIONS: Our data indicate that extracellular matrix-related molecules such as POSTN, TNC, TGFβ, and angiogenic factors have important roles in promoting the development of FVMs associated with PDR. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  VEGF; angiogenesis; fibrosis; microarray; proliferative vitreoretinal disease

Mesh:

Substances:

Year:  2015        PMID: 25604687     DOI: 10.1167/iovs.14-15589

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  28 in total

1.  Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis.

Authors:  Jonathan D Lam; Daniel J Oh; Lindsay L Wong; Dhanesh Amarnani; Cindy Park-Windhol; Angie V Sanchez; Jonathan Cardona-Velez; Declan McGuone; Anat O Stemmer-Rachamimov; Dean Eliott; Diane R Bielenberg; Tave van Zyl; Lishuang Shen; Xiaowu Gai; Patricia A D'Amore; Leo A Kim; Joseph F Arboleda-Velasquez
Journal:  Diabetes       Date:  2017-04-11       Impact factor: 9.461

Review 2.  Periostin in vitreoretinal diseases.

Authors:  Shigeo Yoshida; Takahito Nakama; Keijiro Ishikawa; Shintaro Nakao; Koh-Hei Sonoda; Tatsuro Ishibashi
Journal:  Cell Mol Life Sci       Date:  2017-09-14       Impact factor: 9.261

3.  Gene expression in retinal ischemic post-conditioning.

Authors:  Konrad Kadzielawa; Biji Mathew; Clara R Stelman; Arden Zhengdeng Lei; Leianne Torres; Steven Roth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-05       Impact factor: 3.117

4.  Tenascin-C secreted by transdifferentiated retinal pigment epithelial cells promotes choroidal neovascularization via integrin αV.

Authors:  Yoshiyuki Kobayashi; Shigeo Yoshida; Yedi Zhou; Takahito Nakama; Keijiro Ishikawa; Yuki Kubo; Mitsuru Arima; Shintaro Nakao; Toshio Hisatomi; Yasuhiro Ikeda; Akira Matsuda; Koh-Hei Sonoda; Tatsuro Ishibashi
Journal:  Lab Invest       Date:  2016-09-26       Impact factor: 5.662

5.  Mining the proliferative diabetic retinopathy-associated genes and pathways by integrated bioinformatic analysis.

Authors:  Haiyan Sun; Yahui Cheng; Zhipeng Yan; Xiaokun Liu; Jun Zhang
Journal:  Int Ophthalmol       Date:  2020-01-17       Impact factor: 2.031

6.  Increased expression of periostin and tenascin-C in eyes with neovascular glaucoma secondary to PDR.

Authors:  Keijiro Ishikawa; Ri-Ichiro Kohno; Kenichiro Mori; Yusuke Murakami; Shintaro Nakao; Masato Akiyama; Shigeo Yoshida; Koh-Hei Sonoda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-20       Impact factor: 3.117

7.  Anti-Inflammatory Role of Netrin-4 in Diabetic Retinopathy.

Authors:  Sergio Crespo-Garcia; Nadine Reichhart; Norbert Kociok; Sergej Skosyrski; Antonia M Joussen
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

8.  In-depth transcriptomic analysis of human retina reveals molecular mechanisms underlying diabetic retinopathy.

Authors:  Kolja Becker; Holger Klein; Eric Simon; Coralie Viollet; Christian Haslinger; German Leparc; Christian Schultheis; Victor Chong; Markus H Kuehn; Francesc Fernandez-Albert; Remko A Bakker
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

9.  Assessment of circulating fibrotic proteins (periostin and tenascin -C) In Type 2 diabetes mellitus patients with and without retinopathy.

Authors:  A Indumathi; Gandhipuram Periyaswamy Senthilkumar; Kuppuswamy Jayashree; K Ramesh Babu
Journal:  Endocrine       Date:  2022-03-10       Impact factor: 3.925

10.  Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy.

Authors:  Chi-Hsiu Liu; Zhongxiao Wang; Ye Sun; John Paul SanGiovanni; Jing Chen
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.